Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Bristol-Myers Squibb Co’s stock clocked out at $51.2, down -0.02% from its previous closing price of $51.21. In other words, the price has decreased by -$0.02 from its previous closing price. On the day, 9.71 million shares were traded. BMY stock price reached its highest trading level at $51.48 during the session, while it also had its lowest trading level at $50.44.
Ratios:
To gain a deeper understanding of BMY’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.32 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.81. For the most recent quarter (mrq), Quick Ratio is recorded 1.17 and its Current Ratio is at 1.27. In the meantime, Its Debt-to-Equity ratio is 2.75 whereas as Long-Term Debt/Eq ratio is at 2.50.
Upgrades & Downgrades
In the most recent recommendation for this company, Scotiabank on November 13, 2025, initiated with a Sector Perform rating and assigned the stock a target price of $45. On August 05, 2025, Daiwa Securities Downgraded its rating to Neutral which previously was Outperform but kept the price unchanged to $42.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 02 ’25 when Elkins David V sold 56,000 shares for $47.33 per share. The transaction valued at 2,650,480 led to the insider holds 167,379 shares of the business.
Elkins David V bought 56,000 shares of BMY for $2,648,800 on Sep 02 ’25. On Aug 02 ’25, another insider, Short Bartie Wendy, who serves as the EVP, Corporate Affairs of the company, sold 378 shares for $44.23 each. As a result, the insider received 16,719 and left with 5,066 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BMY now has a Market Capitalization of 104230559744 and an Enterprise Value of 138817552384. As of this moment, Bristol-Myers’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.29, and their Forward P/E ratio for the next fiscal year is 8.57. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.12. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.17 while its Price-to-Book (P/B) ratio in mrq is 5.62. Its current Enterprise Value per Revenue stands at 2.89 whereas that against EBITDA is 7.224.
Stock Price History:
The Beta on a monthly basis for BMY is 0.30, which has changed by -0.08210826 over the last 52 weeks, in comparison to a change of 0.14045572 over the same period for the S&P500. Over the past 52 weeks, BMY has reached a high of $63.33, while it has fallen to a 52-week low of $42.52. The 50-Day Moving Average of the stock is 9.92%, while the 200-Day Moving Average is calculated to be 4.57%.
Shares Statistics:
It appears that BMY traded 16.44M shares on average per day over the past three months and 14550730 shares per day over the past ten days. A total of 2.04B shares are outstanding, with a floating share count of 2.03B. Insiders hold about 0.18% of the company’s shares, while institutions hold 81.03% stake in the company. Shares short for BMY as of 1764288000 were 33891065 with a Short Ratio of 2.06, compared to 1761868800 on 32070775. Therefore, it implies a Short% of Shares Outstanding of 33891065 and a Short% of Float of 1.67.
Dividends & Splits
With its trailing 12-month dividend rate of 2.48, BMY has a forward annual dividend rate of 2.48. Against a Trailing Annual Dividend Yield of 0.048428044. The stock’s 5-year Average Dividend Yield is 3.83.
Earnings Estimates
The dynamic stock of Bristol-Myers Squibb Co (BMY) is currently attracting attention from 17.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $1.49, with high estimates of $1.86 and low estimates of $1.23.
Analysts are recommending an EPS of between $6.68 and $6.4 for the fiscal current year, implying an average EPS of $6.55. EPS for the following year is $5.98, with 27.0 analysts recommending between $7.27 and $5.12.
Revenue Estimates
In. The current quarter, 16 analysts expect revenue to total $12.25B. It ranges from a high estimate of $12.53B to a low estimate of $11.87B. As of. The current estimate, Bristol-Myers Squibb Co’s year-ago sales were $12.34BFor the next quarter, 16 analysts are estimating revenue of $10.58B. There is a high estimate of $11.38B for the next quarter, whereas the lowest estimate is $10.1B.
A total of 23 analysts have provided revenue estimates for BMY’s current fiscal year. The highest revenue estimate was $48.3B, while the lowest revenue estimate was $47.56B, resulting in an average revenue estimate of $48B. In the same quarter a year ago, actual revenue was $48.3BBased on 26 analysts’ estimates, the company’s revenue will be $44.04B in the next fiscal year. The high estimate is $47.74B and the low estimate is $41.97B.
